| BETH ISRAEL DEACONESS MEDICAL CENTER Patent applications |
| Patent application number | Title | Published |
|---|
| 20120045472 | Biochemically Stabilized HIV-1 ENV Trimer Vaccine - Stabilized trimers of a clade A strain and a clade C strain of HIV-1 are provided. Broadly neutralizing antisera against HIV-1, methods of making broadly neutralizing antisera against HIV-1, broadly neutralizing vaccines against HIV-1, as well as methods of treating subjects infected with HIV, preventing HIV infection, and inhibiting HIV-mediated activities are also provided. | 02-23-2012 |
| 20110301328 | POLYVALENT VACCINE - The present invention relates, in general, to an immunogenic composition (e.g., a vaccine) and, in particular, to a polyvalent immunogenic composition, such as a polyvalent HIV vaccine, and to methods of using same. The invention further relates to methods that use a genetic algorithm to create sets of polyvalent antigens suitable for use, for example, in vaccination strategies. | 12-08-2011 |
| 20110280825 | EXTRACORPOREAL DEVICES AND METHODS OF TREATING COMPLICATIONS OF PREGNANCY - The invention features extracorporeal methods for the treatment of a subject having a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia. The invention also features devices used for the extracorporeal treatment of subjects have a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia. | 11-17-2011 |
| 20110243956 | METHODS OF DIAGNOSING AND TREATING COMPLICATIONS OF PREGNANCY - Disclosed herein are methods for diagnosing a pregnancy related hypertensive disorder or a predisposition to a pregnancy related hypertensive disorder by measuring the level or biological activity of soluble endoglin. Also disclosed herein are methods for treating a pregnancy related hypertensive disorder, such as pre-eclampsia and eclampsia, using compounds that alter soluble endoglin levels or biological activity. | 10-06-2011 |
| 20110150915 | POLYVALENT VACCINE - The present invention relates, in general, to an immunogenic composition (e.g., a vaccine) and, in particular, to a polyvalent immunogenic composition, such as a polyvalent HIV vaccine, and to methods of using same. The invention further relates to methods that use a genetic algorithm to create sets of polyvalent antigens suitable for use, for example, in vaccination strategies. | 06-23-2011 |
| 20110071142 | IDENTIFICATION AND USE OF SMALL MOLECULES TO MODULATE TRANSCRIPTION FACTOR FUNCTION AND TO TREAT TRANSCRIPTION FACTOR ASSOCIATED DISEASES - The present invention relates to methods of identifying small molecule candidate agents capable of modulating transcription factor function such that the function/expression of a target transcription factor and/or proteins downstream of this target protein comprises the screening of small molecule libraries using in silico high throughput docking for candidate small molecules/agents that are selectively identified for their ability to target and disrupt the transcription factor-DNA interface through unique transcription factor and/or DNA descriptors that are defined within a pharmacophore, and then testing/evaluating the candidate agents identified above through one or more in vitro assays for their ability to modulate transcription factor function including expression of this target protein and/or proteins that are downstream of the target transcription factor. The present invention also relates to various compounds described herein (e.g., a compound of Formula XI), their pharmaceutically acceptable salts and to methods of using said compounds as described herein. | 03-24-2011 |
| 20110046083 | ACTIVATORS OF PYRUVATE KINASE M2 AND METHODS OF TREATING DISEASE - The invention described herein features methods, compositions, and kits for the use of activators of PKM2 for the treatment, prevention, or amelioration of diseases related to PKM2 function, including, e.g., cancer, diabetes, atherosclerosis, restenosis, obesity, autoimmune disorders, and proliferative disorders. | 02-24-2011 |
| 20110045058 | TRANSFECTION REAGENT - The invention described herein features methods, compositions, and kits for introducing a nucleic acid molecule or biologically active molecule into a eukaryotic cell in vitro or in vivo utilizing a reagent containing energy-rich additives. | 02-24-2011 |
| 20110014197 | METHODS OF TREATING PRE-ECLAMPSIA OR ECLAMPSIA - Disclosed herein are methods for treating pre-eclampsia and eclampsia using compounds that increase VEGF or PlGF levels or compounds that decrease sFlt-1 levels. Compounds that inhibit the binding of VEGF or PlGF to sFlt1—are also disclosed herein for the treatment of pre-eclampsia or eclampsia. | 01-20-2011 |
| 20100310574 | METHODS AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF STATIN-INDUCED MYOPATHY - The invention provides compositions and kits containing an atrogin-1 inhibitor compound useful for the treatment of a statin-mediated myopathy. Kits for the diagnosis of a statin-mediated myopathy are also provided. The invention further features methods for treating or preventing a statin-mediated myopathy in a subject via administration of a therapeutically effective amount of an atrogin-1 inhibitor compound. The invention further provides methods of diagnosing a subject as having a propensity to develop a statin-induced myopathy and methods of monitoring a statin-induced myopathy or a propensity to develop a statin-mediated myopathy in a subject. The invention also features methods for identifying a compound for the treatment of a statin-mediated myopathy and methods of identifying a statin compound as having the propensity to induce a statin-mediated myopathy. | 12-09-2010 |
| 20100291054 | NOVEL REGULATORY T CELLS AND USES THEREOF - The invention provides isolated regulatory T cells and methods of obtaining regulatory T cells. The invention also provides methods for inhibiting an antigen-specific immune response (e.g., graft rejection, an autoimmune disorder, graft versus host disease, a response to a tumor cell, a response to an infection, and a response to an allergen) in a subject requiring administering an isolated regulatory T cell to the subject. The invention further provides methods for treating or modulating an antigen-specific immune response in a subject requiring administering a regulatory T cell to the subject. | 11-18-2010 |
| 20100280104 | METHODS AND KITS FOR DIAGNOSIS AND TREATMENT OF CELL-CELL JUNCTION RELATED DISORDERS - We have discovered that loss of Filamin A function results in weakened cell-cell junctions and vascular defects in genetically engineered mice. In addition, we have shown that patients with mutations in the gene coding for Filamin A exhibit high rates of cardiovascular disorders. On the basis of this discovery, the present invention features methods and kits for diagnosis of cell-cell junction related disorders (e.g., atherosclerosis, aortic aneurysm, or any disease described herein), as well as screening methods | 11-04-2010 |
| 20100239546 | BACTERIAL MEDIATED TNF ALPHA GENE SILENCING - Methods are described for the delivery of one or more small interfering RNAs (siRNAs) to a eukaryotic cell using a bacterium. Methods are also described for using this bacterium to regulate gene expression in eukaryotic cells using RNA interference, and methods for treating an inflammatory disease or disorder. The bacterium includes one or more siRNAs or one or more DNA molecules encoding one or more siRNAs. Vectors are also described for use with the bacteria of the invention for causing RNA interference in eukaryotic cells. | 09-23-2010 |
| 20100221243 | METHODS AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF DISEASES CHARACTERIZED BY VASCULAR LEAK, HYPOTENSION, OR A PROCOAGULANT STATE - Disclosed herein are methods for treating a vascular leak disorder, hypotension, or a procoagulant state using angiopoietin-2 (Ang-2) antagonist compounds. Also disclosed are methods for treating a vascular leak disorder associated with high dose IL-2 therapy using angiopoietin-2 antagonist compounds. Methods for diagnosing and monitoring vascular leak disorders, hypotension, or a procoagulant state that include the measurement of Ang-2 polypeptide or nucleic acid levels are also disclosed. Methods for inducing a vascular leak using an Ang-2 agonist are also disclosed. | 09-02-2010 |
| 20100168052 | Treatment of EBV and KHSV Infection and Associated Abnormal Cellular Proliferation - A method and composition for the treatment, prevention and/or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or excipient. | 07-01-2010 |
| 20100136001 | Methods and compositions for the treatment and diagnosis of vascular inflammatory disorders or endothelial cell disorders - Disclosed herein are methods for treating a vascular inflammatory disorder or endothelial cell disorder using inhibitor compounds that inhibit the expression or biological activity of Tie-1, Tie-1 endodomain, thrombin, VEGFR2, VEGFR2 endodomain, EphA2, and any of the cytokines or kinases that are upregulated by activation of Tie-1 or thrombin, as provided herein. Also disclosed are the use of combinations of inhibitor compounds or the use of an eNOS activator compound in combination with any one or more of the inhibitor compounds. Also disclosed are methods for inhibiting the pro-coagulant activity of thrombin using a Tie-1 or Tie-1 endodomain inhibitor compound or an EphA2 inhibitor compound. Methods for diagnosing and monitoring vascular inflammatory disorders or endothelial cell disorders that include the measurement of any of the polypeptides or nucleic acid molecules of the invention are also disclosed. | 06-03-2010 |
| 20090248143 | PERCUTANEOUS AORTIC VALVE ASSEMBLY - The present invention provides devices and methods for the treatment of cardiovascular valve diseases such as aortic stenosis. A vascular valve assembly is formed from two or more valve devices, each of which contains a valve mounted in a stent. The individual valve devices are brought to the site of the defective valve by standard percutaneous catheterization methods. Lateral expansion of the stents at the site of valve replacement produces a functioning valve assembly. Appropriate sizing and number of valve devices prevents regurgitation and migration. The assembly of two or more smaller valve devices at the site of a defective valve prevents complications due to the large size of single valve prostheses. | 10-01-2009 |
| 20090214572 | Methods and compositions for the treatment and diagnosis of endothelial cell disorders and angiogenic disorders - The invention features methods and compositions for treating and preventing angiogenic disorders and endothelial cells disorders using HspA12B antagonist and HspA12B agonist compounds, respectively. | 08-27-2009 |
| 20090170767 | Soluble Endoglin Compounds for the Treatment and Prevention of Cancer - Disclosed herein are soluble endoglin compounds and kits, pharmaceutical compositions, and articles of manufacture containing soluble endoglin compounds. Also disclosed herein are methods for treating an angiogenesis disorder, such as cancer, using soluble endoglin compounds, provided alone or in combination with a chemotherapeutic agent, an angiogenesis inhibitor, or an antiproliferative compound. | 07-02-2009 |
| 20090143645 | Catheter guided endotracheal intubation - The present invention relates to a guided endotracheal intubation endoscope. A guide catheter is used to position an endoscope and a tube for intubation of a patient. The endoscope can include a steering device for steering the endoscope in at least two directions, as well as suction, irrigation and retraction devices for maintaining a clear field of view. | 06-04-2009 |
| 20090117588 | Methods of diagnosing pre-eclampsia or eclampsia - Disclosed herein are kits for diagnosing pre-eclampsia and eclampsia or a propensity to develop pre-eclampsia or eclampsia that include agents for the detection of levels of free placental growth factor in a subject. | 05-07-2009 |
| 20090054344 | ANTI-ANGIOGENIC PROTEINS AND FRAGMENTS AND METHODS OF USE THEREOF - Proteins with anti-angiogenic properties are disclosed, and fragments thereof, and methods of using those proteins and fragments to inhibit or promote angiogenesis. | 02-26-2009 |
| 20090004669 | Methods of diagnosing pre-eclampsia or eclampsia - Disclosed herein are methods for diagnosing pre-eclampsia and eclampsia. Also disclosed herein are methods for treating pre-eclampsia and eclampsia using compounds that increase VEGF or PlGF levels or compounds that decrease sFlt-1 levels. Compounds that inhibit the binding of VEGF or PlGF to sFlt1- are also disclosed herein for the treatment of pre-eclampsia or eclampsia. | 01-01-2009 |
| 20080319315 | Method of reducing interferences in positron emission tomography - Methods and compositions are disclosed that lower the uptake of the radiopharmaceutical FDG, a glucose analog, by brown adipose tissue and the myocardium in FDG-PET/CT scans. The composition is substantially carbohydrate free and includes high levels of lipids. The method uses the composition and doses at particular times before the scan. The method has an advantage over fasting methods since it reduces the uptake by brown adipose tissue and/or myocardium that can be mistaken for cancer on FDG-PET or PET//CT scans or obscures sites of cancer adjacent to the heart. In addition, this permits the identification, monitoring and treatment of coronary artery disease on PET or PET/CT scans. | 12-25-2008 |
| 20080312146 | METH1 and METH2 Polynucleotides and Polypeptides - The present invention relates to novel anti-angiogenic proteins, related to thrombospondin. More specifically, isolated nucleic acid molecules are provided encoding human METH1 and METH2. METH1 and METH2 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic methods for the prognosis of cancer and therapeutic methods for treating individuals in need of an increased amount of METH1 or METH2. Also provided are methods for inhibiting angiogenesis using METH1 or METH2. | 12-18-2008 |
| 20080308744 | Serum Albumin Conjugated to Fluorescent Substances for Imaging - Compositions and methods are disclosed for imaging tissue or a lymphatic or circulatory system, for example, in the near infrared. Dyes that emit wavelengths in the infrared or near infrared regions of the spectrum may be employed on their own, as combinations or complexed with serum albumin, or as part of a covalent conjugate with serum albumin. | 12-18-2008 |
| 20080214470 | Pin1-Modulating Compounds and Methods of Use Thereof - The invention is directed to peptide modulators of Pin1 and Pin1-related proteins and the use of such modulators for treatment of Pin1 associated states, e.g., for the treatment of cancer or neurodegenerative disease. | 09-04-2008 |
